Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice

Access the webinar recording

Thanks for your interest in our recent Fully Human Antibody Discovery Using Nanovials and Plasma Cells From ATX-GK™ Mice webinar. Please fill out your contact information, and we will email you shortly with a link and passcode to access the recording.

Our approach

Plasma cells are an important source of antibodies and are important to harvest during an antibody discovery campaign. However, because they display no to low levels of antibodies on their surface, detecting and isolating antigen-specific clones is challenging. In this webinar, scientists from Alloy Therapeutics and Partillion Biosciences talk about the opportunity and success behind integrating Partillion Biosciences Nanovial Technology into Alloy’s best-in-class Discovery to Functional Leads workflow and capture antigen-specific plasma cells to augment an antibody discovery campaign.

Learn how:

ATX-Gx™ industry-leading humanized mouse models can be harnessed as in vivo human antibody discovery platform for generating a robust and diverse immune response.
Nanovial technology can screen hundreds of thousands of fragile antibody-secreting plasma without the need for expensive instrumentation or lengthy workflows.
Plasma cells are a rich source of high affinity antibodies that have therapeutic potential.

Schedule a consultation

Webinar Speakers

Targeting GPCRs with Alloy Antibody Discovery Services

Access the white paper

Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.

G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.

Keyway TCR Mimic Discovery Webinar

Access the webinar recording

I’d like more material about Keyway TCR Discovery

Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Upon filling out this form, you will receive an email with a link to the webinar recording.